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Abstract: It has been hypothesized that gluten-dependent production of anti-tissue-transglutaminase
2 (anti-TG2) antibodies may occur only at an intestinal level. We have investigated intestinal
production of anti-TG2 antibodies in 136 patients with normal serum levels of anti-TG2 antibodies
and normal duodenal mucosa. Intestinal deposits of anti-TG2 antibodies were evaluated by
immunofluorescence and anti-TG2 antibodies released in organ culture supernatants measured
by ELISA. Intestinal antibody libraries were obtained from 10 subjects. Immunohistochemistry for
CD25+, CD3+, and TCR-γδ+ was assessed in subjects with positive (n = 32) and negative (n = 31)
intestinal anti-TG2 antibodies. Globally 33/136 (24%) seronegative patients produced anti-TG2
autoantibodies at an intestinal level. Antibody libraries analysis confirmed the anti-TG2 antibodies
mucosal production in all (n = 8) positive subjects. Lamina propria CD25+ cell count was significantly
(p < 0.05) higher in patients with intestinal anti-TG2. Moreover, 13/32 (41%) of them showed high
TCR-γδ+/CD3+ ratios. Intestinal anti-TG2 antibody production does not show absolute specificity for
CD. It is seen more often in association with inflamed mucosa. Further investigations are necessary
to prove the possible role of dietary gluten.
Keywords: celiac disease; potential celiac disease; intestinal anti-transglutaminase 2 antibodies;
TCR-γδ+ intraepithelial lymphocytes
1. Introduction
Celiac disease (CD) is considered a systemic immune-mediated disorder elicited by gluten
and related prolamines in genetically susceptible individuals [1]. The presence in the serum of
anti-tissue-transglutaminase 2 (anti-TG2) antibodies is considered a sensitive and specific biomarker
for CD [2].
Anti-TG2 antibodies are produced primarily at an intestinal level by specific B lymphocytes and, using
phage display library technology, it has been proven that these antibodies are synthesized in CD patients
with preferential use of IGVH5-51 gene family [3]. Once produced, anti-TG2 antibodies can deposit in the
small intestinal mucosa [4], even before they can be detected in the circulation [5,6]. Furthermore, TG2
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specific IgA deposition precedes the formation of small intestinal lesion in CD [6,7] as it can be detected
also in potential CD patients [6,8,9], i.e., patients showing positive serology for CD-specific antibodies,
but architecturally normal intestinal mucosa [10]. The presence of mucosal deposits of anti-TG2 antibodies
seems to be a predictive marker of future evolution to villous atrophy, as it was seen more often in those
potential patients that progress to overt CD than in those remaining in early phase of disease [5,6,8].
Several investigators have shown that intestinal anti-TG2 IgA deposits are also detectable in
subjects with diagnosis other than CD with a prevalence ranging from 5 to 20% [11–13]; in our
experience, up to 12% of pediatric non-CD patients shows mucosal deposits [13]. A similar percentage
of non-CD patients producing anti-TG2 antibodies only at an intestinal level has been recently shown
by us by measuring anti-TG2 antibodies secreted into supernatants from organ culture of small
intestinal biopsy [9]. This phenomenon could be not specific for CD and merely attributable to
intestinal inflammation; alternatively, it could be suggestive of a very early condition of gluten
reactivity. The subjects initially producing anti-TG2 antibodies only at an intestinal level could become
serum positive later and eventually develop small intestinal mucosal damage.
Here we aimed to investigate the intestinal production of anti-TG2 antibodies in patients with
normal serum levels of such antibodies and to relate that production to immunohistochemical markers
of gluten-dependent enteropathy.
2. Materials and Methods
2.1. Patients
In this retrospective study, we considered 283 patients enrolled between January 2001 and December
2015 at the Department of Pediatrics of the University Federico II in Naples, for whom samples of small
intestinal biopsies fixed in formalin, biopsies frozen in optimal cutting temperature compound and organ
culture supernatants were available. One-hundred and forty-seven of 283 patients (40 males, mean age 6.9
years) had high serum levels of anti-TG2 antibodies and/or positive serum anti-endomysium antibodies,
they underwent a small intestinal biopsy for suspicion of CD. Forty-four of 147 showed a lesion of intestinal
mucosa type Marsh 3, according to Marsh classification modified by Oberhuber et al. [14], and had a final
diagnosis of CD according to ESPGHAN criteria (1990, 2012) [1,15]; they were referred to as Active CD.
One-hundred and three of 147 patients had a normal or slightly infiltrated duodenal mucosa classified as
Marsh 0 (n = 40) and Marsh 1 (n = 63). They were defined as Potential CD. One-hundred and thirty-six out
of 283 subjects (66 males, mean age 7 years) had normal values of anti-TG2 antibodies and/or absence
of anti-endomysium antibodies in the serum. We found that 130/136 showed duodenal mucosa Marsh
0 (n = 98) or Marsh 1 (n = 32), and 6/136 showed Marsh 3a mucosa. They had final diagnosis other
than CD: gastroesophageal reflux (n = 52), gastrointestinal functional disorders (n = 32), type 1 diabetes
(n = 19), Helicobacter pylori infection (HP, n = 10), eosinophilic esophagitis (n = 8), first degree relatives of
CD patients (n = 6), iron deficiency anemia (n = 2), failure to thrive (n = 2), inflammatory bowel disease
(n = 2), and autoimmune hepatitis (n = 2). They represented the Non-CD group.
IgA deficiency was ruled out in all enrolled subjects. The use of biopsy specimens was authorized
by the Institutional Ethical Committee.
2.2. Detection of Mucosal Deposits of anti-TG2 IgA Antibodies
The presence of intestinal deposits of anti-TG2 IgA was investigated on duodenal frozen sections
from all patients. Five µm sections were stained using a double-immunofluorescence method,
as previously described [16]. The stained sections were evaluated using a fluorescent microscope
(Axioskop2 plus; Zeiss MicroImaging Inc., Milan, Italy).
2.3. Biopsy Specimens and Organ Culture
During upper gastrointestinal endoscopy, at least four duodenal biopsies were taken from
all patients and fixed in 10% formalin, embedded in paraffin, and then treated for histological
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and morphometrical analysis performed by light microscopy and by two experienced pathologists.
A villous height crypt depth ratio ≥2.2 was considered normal [17]. One further duodenal specimen
was embedded in an optimal cutting temperature compound (OCT; Killik, Bio-Optica, Milan, Italy) and
stored in liquid nitrogen until used. The last fragment was placed on a stainless steel mesh positioned
over the central well of an organ culture dish with the villous surface of the specimens upper-most in
medium containing RPMI 1640 (80%; Sigma, Milan, Italy) supplemented with fetal bovine serum (15%;
Life Technologies-GibcoBRL, Milan, Italy), L-glutamina (2 mM; Life Technologies-GibcoBRL), penicillin
(100 U/mL), streptomycin (100 µg/mL) (Life Technologies-GibcoBRL), and insulin (1 mg/mL; Sigma).
The biopsy was cultured for 24 h at 37 ◦C with the culture medium; it was placed in a sterile anaerobic
jar which was gassed with 95% oxygen/5% carbon dioxide. The supernatants were collected and
stored at −80 ◦C until they were analyzed.
2.4. Measurement of Anti-TG2 IgA Antibodies Secreted into Culture Supernatants
Mucosal anti-TG2 IgA antibodies secreted into culture supernatants were measured in undiluted
supernatants by enzyme-linked immunosorbent assay (ELISA; EU-tTG IgA kit; Eurospital S.p.A.,
Trieste, Italy), according to the manufacturer’s instructions. The cut-off value was previously calculated
as 2.8 U/mL [9]. When the value of anti-TG2 was higher than the last point of standard curve,
supernatants were diluted 1:20 in culture medium.
2.5. Phage Display Library
Total tissue RNA was extracted from whole duodenal biopsies using TRIZOL reagent (Gibco Life
Technologies, Milan, Italy). cDNAs were generated from total RNA using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA). Selective IgA IGVH5-51 genes were
amplified from cDNA and assembled into single chain fragment-variable (scFv) fragments by cloning
into phagemid vector pDAN5 as previously reported [18]. After selection, by affinity chromatography,
45 individual clones were screened for reactivity to TG2 by ELISA. To value their diversity, clones were
sequenced. The VH family and the V gene were analyzed using IMGT V-quest database [19].
2.6. Immunohistochemistry
Immunohistochemical staining for CD3+, TCR-γδ+, and CD25+ cells was performed using
four-µm frozen duodenal sections as previously reported [20]. Briefly, duodenal cryostat sections were
fixed in acetone for 10 min. After incubation with normal rabbit serum (1:100, Dako, Copenhagen,
Denmark) for 20 min, sections were covered with anti-CD3 (1:100; Dako), anti-TCRγδ (1:60; Thema
Ricerca, Castenaso (BO), Italy), or anti-CD25 (1:20; Exalpha biological Inc., Shirley, MA, USA),
monoclonal antibodies for 1 h. The sections treated for detection of CD3+ and TCR-γδ+ cells were then
covered with anti-mouse Envision system-HRP (Dako) for 45 min. The sections treated for detection of
CD25+ cells were then covered with rabbit anti-mouse immunoglobulins for 30 min and successively
with monoclonal mouse alkaline phosphatase anti-alkaline phosphatase (APAAP; 1:40; Sigma-Aldrich,
Milan, Italy) for 30 min. 2-amino-9-ethyl-carbazole (AEC) (Sigma-Aldrich, Milan, Italy) and new
fuchsine were used as peroxidase and phosphatase alkaline substrate, respectively. Finally, sections
were counterstained with Mayer’s hematoxylin (Sigma-Aldrich) and mounted with Aquamount (BDH,
Poole, England). Monoclonal antibodies were diluted in Tris pH 7.4. All incubations were conducted
at room temperature in a humid chamber. As a negative control, mouse IgG2a/IgG1 (Dako) replaced
the primary antibody.
The number of stained cells per millimeter of epithelium determined the density of cells expressing
CD3 and TCR-γδ in the intraepithelial compartment. Cut-off values for CD3+ and TCR-γδ+ cells
were 34/mm and 3.4/mm of epithelium, respectively. On the other hand, the number of cells
expressing CD25 in the lamina propria was evaluated within a total area of 1 mm2. The cut-off
value for CD25+ cells was 4/mm2 lamina propria. Morphometric evaluations were performed using a
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microscope (Axioscop, Zeiss MicroImaging Inc., Milan, Italy) with a calibrated lens aligned parallel to
the muscolaris mucosae.
2.7. Statistics
Statistical analysis was performed using GraphPad Prism 4 for Windows, version 4.03. Data were
compared by Mann–Whitney test and Fisher’s χ2 test. A p-value < 0.05 was considered to be significant.
2.8. Ethical Approval
Written informed consent was obtained from parents of children enrolled. The study protocol
was approved by the Ethical Committee of the University ‘Federico II’ Naples, Italy (CE 230/05).
3. Results
3.1. Intestinal Anti-TG2 Antibodies Are Also Produced in Non-CD Patients
Mucosal deposits of IgA anti-TG2 antibodies were detected in 40 of 44 Active CD (90.9%), 72 of
103 Potential CD (69.6%), and 25 of 136 Non-CD patients (18.3%). In CD patients, they presented as
thick bands under surface epithelium, around crypts and vessels. In potential CD subjects the bands
were less thick with a patchy distribution. In patients with diagnosis other than CD, the staining
appeared weak, in some cases deposits were evident only around some crypts.
On the other hand, in all CD patients in the active phase of disease (100%), in 101/103 (98%)
patients with potential CD and in 13/136 subjects (10%) with diagnosis other than CD, anti-TG2
antibodies could be measured in culture supernatants. Anti-TG2 antibody titers ranged from 4.21 to
2020.3 U/mL in CD and from 3.3 to 29.3 U/mL in Non-CD patients.
Our data showed that in total 33/136 Non-CD patients (24.3%) had evidence of intestinal
production of anti-TG2 antibodies: they were defined below as Positive Non-CD patients. Five
of 136 Non-CD subjects were found positive for both assays.
The 33 Positive Non-CD patients had following diagnoses: type 1 diabetes (n = 10),
gastroesophageal reflux (n = 9), gastrointestinal functional disorders (n = 6), first degree relatives of
CD patients (n = 3), eosinophilic esophagitis (n = 3), HP infection (n = 2). 29/33 patients had Marsh 0
(n = 24) or Marsh 1 (n = 5) duodenal mucosa and the remaining 4 patients had a Marsh 3a mucosa.
All CD patients had HLA-DQ2 and/or DQ8 haplotypes. The celiac disease-type HLA was known
in 14/33 Positive Non-CD and in 5/31 Negative Non-CD patients. It was found that 12/13 Positive
Non-CD were HLA-DQ2 and/or -DQ8 positive, 2 patients showed DQA1*05-DQB1*03 haplotype,
the most frequent HLA haplotype in DQ2/DQ8 negative CD patients [21]. Three of the five Negative
Non-CD patients were HLA-DQ2 positive, the last two were HLA-DQ2/DQ8 negative.
3.2. Phage Display Technology Confirms the Intestinal Production of Anti-TG2 Antibodies in Non-CD Patients
To confirm the intestinal production of anti-TG2 antibodies in positive Non-CD patients, we
created IGVH5-51 antibody libraries against TG2 from biopsy specimens of 8/33 Positive Non-CD
patients (six positive to detection of mucosal deposits of anti-TG2 antibodies and two who secreted
anti-TG2 into culture supernatants); two Non-CD patients negative to both the above mentioned tests
served as controls (Negative Non-CD).
Antibody clones recognizing TG2 were isolated from intestinal biopsies of all Positive Non-CD
patients. The number of anti-TG2 antibody clones ranged from 2.2% to 13.3%. No difference in percentage
of anti-TG2 specific clones was observed between the patients positive only to detection of mucosal
deposits and the patients positive only to measurement of anti-TG2 antibodies into culture supernatants.
No anti-TG2 antibody clones were isolated from biopsy samples of the two patients double negative to
the above mentioned tests (Table 1). All positive Non-CD patients, with the exception of the two affected
by type 1 diabetes, produced anti-TG2 antibodies with a preferential use of VH5 gene family. The type 1
diabetes patients produced anti-TG2 antibodies mainly belonging to the VH3 gene family.
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Table 1. Laboratory data of the intestinal immune anti-TG2 response from the 10 selected
Non-CD Patients
Patient Deposits Anti-TG2 Anti-TG2 intoSupernatants Anti-TG2 VH HLA
n = 1 Non-CD Neg + VH5 ND
n = 2 Non-CD Neg + VH5 ND
n = 3 Non-CD + Neg VH5 ND
n = 4 Non-CD + Neg VH5 DQ2/DQ8negative (DQ7DR5)
n = 5 Non-CD + Neg VH5 ND
n = 6 Non-CD Neg Neg No DQ2 positive
n = 7 Non-CD + Neg VH5, VH3 DQ2/DQ8 positive
n = 8 Non-CD + Neg VH5, VH3 DQ2/DQ8 positive
n = 9 Non-CD Neg Neg No DQ2 positive
n = 10 Non-CD Neg Neg No DQ2 positive
Anti-TG2 = anti-tissue transglutaminase2 antibodies; ND = not determined.
3.3. Positive Non-CD Patients Presented Signs of Activated Cell-Mediated Mucosal Immunity
In order to assess the activation of mucosal immunity and in particular of a gluten-related
deranged immune response, the density of mononuclear cells expressing CD25 in lamina propria and
the density of CD3+ and TCR-γδ+ cells in epithelial compartment were investigated in 32/33 Positive
Non-CD patients and in 31/103 Non-CD patients negative to both above-mentioned tests (Negative
Non-CD) that served as control group. Twelve of 32 (37%) Positive Non-CD and 5/31 (16%) Negative
Non-CD presented with alteration of two or more of the above-mentioned markers, (Table 2).
Table 2. Immunohistochemical markers of gluten-related enteropathy tested in 32 Positive Non-CD
patients and in 31 Negative Non-CD patients.
Marker Positive No-CD Patients Negative No-CD Patients X2 Fisher’s Exact Test
CD25+ cells > cutoff 24/32 (75.0%) 14/31 (54.1%) p = 0.02
CD3+ cells > cutoff 7/32 (21.8%) 5/31 (16.0%) p = 0.5
TCR-γδ+ cells > cutoff 11/32 (34.4%) 6/31 (19.3%) p = 0.2
TCR-γδ+/CD3+ ratio > cutoff 13/32 (40.6%) 9/31 (29.0%) p = 0.4
In the Positive Non-CD group, 7 of 32 patients (21.8%) presented increased number of CD3+
intraepithelial lymphocytes (IELs) (mean ± SD = 28.9 ± 20.5 cells) (Figure 1A), 11 of 32 patients
(34.3%) increased number of TCR-γδ+ IELs (mean ± SD = 2.6 ± 2.5 cells) (Figure 1B) and 24 of 32
(75.0%) increased number of lamina propria CD25+ mononuclear cells (mean ± SD = 13.2. ± 15.2 cells)
(Figure 1C). On the contrary in the Negative Non-CD group, high number of CD3+ (26.1 ± 11.0),
TCR-γδ+ (2.0 ± 1.5) and CD25+ (5.7 ± 4.3) cells were found in 5/31 (16.1%), 6/31 (19.3%) and 14/31
(45.1%) patients, respectively (Table 2). Only the percentage of subjects with an increased number of
CD25+ mononuclear cells in lamina propria was significantly higher in Positive Non-CD in comparison
to Negative Non-CD patients (p < 0.05) (Table 2). Likewise the density of CD25+ cells in lamina
propria was significantly higher in Positive Non-CD (13.2 ± 15.12 cells) than that in Negative Non-CD
(5.7 ± 4.31 cells) (p < 0.01) (Figure 2). Finally, we evaluated TCR-γδ+/CD3+ ratio that is considered a
more reliable marker of gluten sensitivity than CD3 and TCR-γδ values considered singularly [20].
41% (13/32) of Positive Non-CD showed TCR-γδ+/CD3+ ratio over cut-off in comparison to 29%
(9/31) of Negative Non-CD (Table 2). The diagnosis of those with high TCR-γδ+/CD3+ ratio were:
gastroesophageal reflux (n = 6), type 1 diabetes (n = 4), eosinophilic esophagitis (n = 2), gastrointestinal
functional disorders (n = 1).
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duodenal sample of one Positive Non-CD patient. 200× magnification. 
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antibodies at intestinal level; the white squares represent Negative Non-CD patients. Horizontal bars 
indicate median values. Mann–Whitney test, ** p < 0.01. 
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In this retrospective study we showed that the great majority of active CD patients produce 
anti-TG2 antibodies at the level of the intestinal mucosa. In our laboratories, two tests were used to 
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Figure 2. Immunohistochemical markers of immune activation in the epithelium and lamina propria
of Non-CD patients. Mononuclear CD25+ cells are increased in Positive Non-CD patients. Each point
represents a single patients. The black points represent Non-CD patients producing anti-TG2 antibodies
at intestinal level; the white squares represent Negative Non-CD patients. Horizontal bars indicate
median values. Mann–Whitney test, ** p < 0.01.
4. Discussion
In this retrospective study we showed that the great majority of active CD patients produce
anti-TG2 antibodies at the level of the intestinal mucosa. In our laboratories, two tests were used to
detect intestinal anti-TG2 antibodies: the first is based on the co-localization of antibodies against
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TG2 and their natural tissue antigen in duodenal cryostat sections by immunofluorescence [4,16];
the second one is an ELISA test performed on supernatants from duodenal biopsy culture [9] and,
in this pediatric population, it has a higher sensitivity compared to deposits detection, confirming our
previous data [9,13]. Moreover, ELISA test detects spontaneous intestinal production of CD-specific
autoantibodies even in the very early stage of the disease. Indeed, it results positive in 98% of potential
CD, whose intestinal mucosa does not show signs of damage and in whom serum levels of anti-TG2
antibodies are lower than those found in the active phase of disease [22]. Of note, mucosal deposits are
detectable only in about 70% of pediatric patients with potential CD, thus suggesting that even very
low antibody production may be detected by ELISA testing in culture supernatants. The absence of
mucosal deposits of anti-TG2 antibodies, more often noted in potential CD, could be due to the low
affinity displayed by these antibodies to their antigen and/or to their lower concentration.
A highly sensitive test able to demonstrate the intestinal production of anti-TG2 antibodies could
be relevant in clinical practice for its possible ability to predict evolution towards mucosal damage.
Moreover, the ability to detect a very early production of intestinal anti-TG2 antibodies could be
helpful to identify a condition of gluten sensitivity in patients with absence of serum CD-associated
autoantibodies [23,24].
On the other hand, we showed that the above-mentioned tests have a high specificity even though
they do not reach 100%. In this particular population, approximately 25% of Non-CD patients produce
anti-TG2 antibodies only at intestinal level. Our data showed that some of those patients without
circulating anti-TG2 antibodies exhibit mucosal deposits of anti-TG2 antibodies with a pattern similar
to that observed in potential CD and/or spontaneously secrete the same antibodies in supernatants
after 24 hours of small intestine culture. The results obtained using the phage display technologies
definitely support the above-mentioned data. Indeed, the construction of antibody libraries from
biopsy samples showed a production of an anti-TG2 specific antibody repertoire dominated by the
usage of VH5-51 gene segment (in 75% of patients), the same used by active CD patients [3,25], and by
the VH3 (in 25%) gene segment. Of interest, the only two first degree relatives of CD patients included
in the phage display library analysis of this study showed a VH5-51 gene usage, confirming a previous
report by Not et al. [24]. Furthermore, two of the patients studied by phage display library have type 1
diabetes and mainly produce VH3 anti-TG2 antibodies, as we already previously published [26]. With
the same technology we were not able to isolate TG2-specific antibody clones from Non-CD patients
who did not present any sign of intestinal anti-TG2 antibody production. Altogether, our data showed
an intestinal production of anti-TG2 antibodies in a subgroup of Non-CD patients.
The demonstration of intestinal production of anti-TG2 antibodies in non-CD patients, poses
the question of whether this finding is related to a deranged mucosal immune response to gluten, as
shown in other settings, such as in first-degree relatives of CD patients [24] or in patients with genetic
gluten intolerance [24,27]. Notably, individuals producing intestinal anti-TG2 antibodies, taken as a
group, more often (75% of them) show inflammatory signs, demonstrated by the increased density
of CD25+ cells, in the small intestinal mucosa as compared to Non-CD subjects lacking evidence of
local anti-TG2 antibodies production. Furthermore, they tend to present increased density of markers
considered specific for gluten-sensitive enteropathy, such as TCR-γδ+ intraepithelial lymphocytes [28]
and increased value of TCR-γδ+/CD3+ ratio [20]. On the other hand, it is known that the increase of
intraepithelial lymphocytes, peculiar of Marsh 1 duodenal lesion, and also the higher intraepithelial
density of TCR-γδ+ lymphocytes have no absolute specificity for CD [29,30].
Our findings are not surprising for subjects with type 1 diabetes and first-degree relatives of
CD patients included in our study group, since they belong to groups at risk to develop CD [28,31],
but are intriguing for individuals unrelated to CD. However, the association between gastrointestinal
disorders such as eosinophilic oesophagitis, gastro-oesophageal reflux disease, or Helicobacter pylori
infection and intestinal production of anti-TG2 antibodies is to date unknown as yet little explored.
HLA typing could be of help as the absence of HLA-DQ2/-DQ8 alleles in these patients
would suggest the hypothesis that the production of anti-TG2 antibodies at intestinal level is not
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exclusive of CD. Although we have typed for HLA only 42% of intestinal anti-TG2 positive Non-CD
patients, all cases but two turned out to be HLA-DQ2/-DQ8 positive and the two negative cases
have DQA1*05-DQB1*03 haplotype, the most frequent HLA haplotype in DQ2/DQ8 negative CD
patients [21].
Both possibilities remain then open: intestinal anti-TG2 IgA production could be due to a general
state of inflammation or could indicate a very early stage of a gluten-dependent pathology. The effect
of a gluten free diet and a more prolonged clinical follow-up could help to establish whether our
finding is expression of a gluten-dependent mucosal response and if those subjects belong to the
spectrum of gluten-related disorders.
Acknowledgments: This work was supported by POR (Progetto Operativo Regionale) Campania 2007/2013.
Title of the project: Benessere dalle Biotecnologie: nuovi processi e prodotti per la Nutraceutica, la Cosmetoceutica
e la Nutrizione Umana, (BenTen).
Author Contributions: Mariantonia Maglio: conceived the study and designed experiments, analyzed and
interpreted the data, wrote the manuscript. Fabiana Ziberna: performed the experiments and analyzed the data.
Rosita Aitoro, Giuliana Lania, Virginia Bassi: performed the experiments. Valentina Discepolo: collected clinical
data and analyzed the data. Erasmo Miele: performed endoscopy. Tarcisio Not: analyzed data and critically
revised the manuscript. Riccardo Troncone: conceived the study and designed experiments, analyzed data and
critically revised the manuscript. Renata Auricchio: conceived the study and designed experiments, critically
revised the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Husby, S.; Koletzko, S.; Korponay-Szabó, I.R.; Mearin, M.L.; Phillips, A.; Shamir, R.; Troncone, R.;
Giersiepen, K.; Branski, D.; Catassi, C.; et al. ESPGHAN Working Group on Coeliac Disease Diagnosis, on
behalf of the ESPGHAN Gastroenterology Committee, European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition. Guidelines for the diagnosis of coeliac disease. J. Pediatr. Gastroenterol. Nutr.
2012, 54, 136–160. [CrossRef] [PubMed]
2. Giersiepen, K.; Lelgemann, M.; Stuhldreher, N.; Ronfani, L.; Husby, S.; Koletzko, S. ESPGHAN Working
Group on Coeliac Disease Diagnosis. Accuracy of diagnostic antibody tests for coeliac disease in children:
Summary of an evidence report. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 229–241. [CrossRef] [PubMed]
3. Marzari, R.; Sblattero, D.; Florian, F.; Tongiorgi, E.; Not, T.; Tommasini, A.; Ventura, A.; Bradbury, A.
Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease. J. Immunol.
2001, 166, 4170–4176. [CrossRef] [PubMed]
4. Korponay-Szabo, I.R.; Halttunen, T.; Szalai, Z.; Laurila, K.; Király, R.; Kovács, J.B.; Fésüs, L.; Mäki, M. In vivo
targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004, 53, 641–648.
[CrossRef] [PubMed]
5. Salmi, T.T.; Collin, P.; Korponay-Szabó, I.R.; Laurila, K.; Partanen, J.; Huhtala, H.; Király, R.; Lorand, L.;
Reunala, T.; Mäki, M.; et al. Endomysial antibody-negative coeliac disease: Clinical characteristics and
intestinal autoantibody deposits. Gut 2006, 55, 1746–1753. [CrossRef] [PubMed]
6. Kaukinen, K.; Peräaho, M.; Collin, P.; Partanen, J.; Woolley, N.; Kaartinen, T.; Nuutinen, T.; Halttunen, T.;
Mäki, M.; Korponay-Szabo, I. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac
disease without villous atrophy: A prospective and randomized clinical study. Scand. J. Gastroenterol. 2005,
40, 564–572. [CrossRef] [PubMed]
7. Salmi, T.T.; Collin, P.; Jarvinen, O.; Haimila, K.; Partanen, J.; Laurila, K.; Korponay-Szabo, I.R.; Huhtala, H.;
Reunala, T.; Mäki, M.; et al. Immunoglobulin A autoantibodies against transglutaminase 2 in the small
intestinal mucosa predict forthcoming celiac disease. Aliment. Pharmacol. Ther. 2006, 24, 541–552. [CrossRef]
[PubMed]
8. Tosco, A.; Salvati, M.V.; Auricchio, R.; Maglio, M.; Borrelli, M.; Coruzzo, A.; Paparo, F.; Boffardi, M.;
Esposito, A.; D’Adamo, G.; et al. Natural history of potential celiac disease in children. Clin. Gastroenterol.
Hepatol. 2011, 9, 320–325. [CrossRef] [PubMed]
Nutrients 2017, 9, 1050 9 of 10
9. Tosco, A.; Aitoro, R.; Auricchio, A.; Ponticelli, D.; Miele, E.; Paparo, F.; Greco, L.; Troncone, R.; Maglio, M.
Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease. Clin. Exp. Immunol. 2013, 171,
69–75. [CrossRef] [PubMed]
10. Ludvigsson, J.F.; Leffler, D.A.; Bai, J.C.; Biagi, F.; Fasano, A.; Green, P.H.; Hadjivassiliou, M.; Kaukinen, K.;
Kelly, C.P.; Leonard, J.N.; et al. The Oslo definitions for coeliac disease and related terms. Gut 2012, 62, 43–52.
[CrossRef] [PubMed]
11. Koskinen, O.; Collin, P.; Korponay-Szabo, I.; Salmi, T.; Iltanen, S.; Haimila, K.; Partanen, J.; Mäki, M.;
Kaukinen, K. Gluten-dependent small bowel mucosal transglutaminase 2-specific IgA deposits in overt and
mild enteropathy coeliac disease. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 436–442. [CrossRef] [PubMed]
12. Koskinen, O.; Collin, P.; Lindfors, K.; Laurila, K.; Mäki, M.; Kaukinen, K. Usefulness of small-bowel mucosal
transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease. J. Clin.
Gastroenterol. 2010, 44, 483–488. [CrossRef] [PubMed]
13. Maglio, M.; Tosco, A.; Auricchio, R.; Paparo, F.; Colicchio, B.; Miele, E.; Rapacciuolo, L.; Troncone, R.
Intestinal deposits of anti-tissue transglutaminase IgA in childhood celiac disease. Dig. Liver Dis. 2011, 43,
604–608. [CrossRef] [PubMed]
14. Oberhuber, G.; Granditsch, G.; Vogelsang, H. The histopathology of coeliac disease: Time for a standardized
report scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 1999, 11, 1185–1194. [CrossRef] [PubMed]
15. Walker-Smith, J.A.; Guandalini, S.; Schmitz, J.; Shmerling, D.H.; Visacorpi, J.K. Report of Working Group of
European Society of Paediatric Gastroenterology and Nutrition. Revised criteria for the diagnosis of celiac
disease. Arch. Dis. Child. 1990, 65, 909–911.
16. Tosco, A.; Maglio, M.; Paparo, F.; Rapacciuolo, L.; Sannino, A.; Miele, E.; Barone, M.V.; Auricchio, R.;
Troncone, R. Immunoglobulin A anti-tissuetransglutaminase antibody deposits in the small intestinal
mucosa of children with no villous atrophy. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 293–298. [CrossRef]
[PubMed]
17. Kurppa, K.; Ashorn, M.; Iltanen, S.; Koskinen, L.L.; Saavalainen, P.; Koskinen, O.; Mäki, M.; Kaukinen, K.
Celiac disease without villous atrophy in children: A prospective study. J. Pediatr. 2010, 157, 373–380.
[CrossRef] [PubMed]
18. Sblattero, D.; Bradbury, A. Exploiting recombination in single bacteria to make large phage antibody libraries.
Nat. Biotechnol. 2000, 18, 75–80. [PubMed]
19. Available online: http://www.imgt.org/IMGT_vquest/share/textes/ (accessed on 1989).
20. Paparo, F.; Petrone, E.; Tosco, A.; Maglio, M.; Borrelli, M.; Salvati, V.M.; Miele, E.; Greco, L.; Auricchio, S.;
Troncone, R. Clinical, HLA and small bowel immunohistochemical features of children with positive serum
antiendomysium antibodies and architecturally normal small intestinal mucosa. Am. J. Gastroenterol. 2005,
100, 2294–2298. [CrossRef] [PubMed]
21. Tinto, N.; Cola, A.; Piscopo, C.; Capuano, M.; Galatola, M.; Greco, L.; Sacchetti, L. High Frequency of
Haplotype HLA-DQ7 in Celiac Disease Patients from South Italy: Retrospective Evaluation of 5535 Subjects
at Risk of Celiac Disease. PLoS ONE 2015, 10, e0138324. [CrossRef] [PubMed]
22. Setty, M.; Discepolo, V.; Abadie, V.; Kamhawi, S.; Mayassi, T.; Kent, A.; Ciszewski, C.; Maglio, M.; Kistner, E.;
Bhagat, G.; et al. Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to
Functions of Intraepithelial Killer Cells and Active Celiac Disease. Gastroenterology 2015, 149, 681–691.
[CrossRef] [PubMed]
23. Troncone, R.; Jabri, B. Coeliac disease and gluten sensitivity. J. Intern. Med. 2011, 269, 582–590. [CrossRef]
[PubMed]
24. Not, T.; Ziberna, F.; Vatta, S.; Quaglia, S.; Martelossi, S.; Villanacci, V.; Marzari, R.; Florian, F.; Vecchiet, M.;
Sulic, A.M.; et al. Cryptic genetic gluten intolerance revealed by intestinal antitransglutaminase antibodies
and response to gluten-free diet. Gut 2011, 60, 1487–1493. [CrossRef] [PubMed]
25. Di Niro, R.; Mesin, L.; Zheng, N.Y.; Stamnaes, J.; Morrissey, M.; Lee, J.H.; Huang, M.; Iversen, R.; Du
Pré, M.F.; Qiao, S.W.; et al. High abundance of plasma cells secreting transglutaminase 2-specific IgA
autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat. Med. 2012, 18,
441–445. [CrossRef] [PubMed]
26. Maglio, M.; Florian, F.; Vecchiet, M.; Auricchio, R.; Paparo, F.; Spadaro, R.; Zanzi, D.; Rapacciuolo, L.;
Franzese, A.; Sblattero, D.; et al. Majority of children with type 1 diabetes produce and deposit anti-tissue
transglutaminase antibodies in the small intestine. Diabetes 2009, 58, 1578–1584. [CrossRef] [PubMed]
Nutrients 2017, 9, 1050 10 of 10
27. Quaglia, S.; De Leo, L.; Ziberna, F.; Vatta, S.; Villanacci, V.; Granzotto, M.; Petix, V.; Martelossi, S.; Di Leo, G.;
Torelli, L.; et al. Intestinal-mucosa anti-transglutaminase antibody assays to test for genetic gluten intolerance.
Cell. Mol. Immunol. 2014, 11, 617–620. [CrossRef] [PubMed]
28. Holm, K.; Maki, M.; Savilahti, E.; Auricchio, R.; Paparo, F.; Spadaro, R. Intraepithelial gamma delta
T-cell-receptor lymphocytes and genetic susceptibility to coeliac disease. Lancet 1992, 339, 1500–1503.
[CrossRef]
29. Tortora, R.; Capone, P.; Imperatore, N.; De Stefano, G.; Gerbino, N.; Leo, M.; Caporaso, N.; Rispo, A.
Predictive value of “Marsh 1” type histology in subjects with suspected cealic disease. Scand. J. Gastroenterol.
2014, 49, 801–806. [CrossRef] [PubMed]
30. Jinga, M.; Balaban, D.V.; Peride, I.; Niculae, A.; DuT¸escu, I.M.; Vasilescu, F.; Mäki, M.; Popp, A.M. Crypt
hyperplastic enteropathy in distal duodenum in Helicobacter pylori infection—Report of two cases without
evidence of celiac disease. Rom. J. Morphol. Embryol. 2017, 58, 685–688. [PubMed]
31. Auricchio, R.; Paparo, F.; Maglio, M.; Franzese, A.; Lombardi, F.; Valerio, G.; Nardone, G.; Percopo, S.;
Greco, L.; Troncone, R. In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. Diabetes
2004, 53, 1680–1683. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
